Cost-Effective HIV PrEP: CAB-LA Transforms Prev...

By Rene Pretorius

April 16, 2025

Summary Cabotegravir long-acting (CAB-LA) delivers a cost-effective HIV PrEP solution. It reduces infections and supports the Ending the HIV Epidemic (EHE) initiative. This review exami...
Cost-Effective Interventions for HIV, Malaria, Syphilis, and TB in 128 Countries
HIV Colorectal Cancer Survival
CKD Prevalence in HIV Patients on TDF: A Global Perspective
New Global AIDS Strategy 2030 Aims to End AIDS Threat by 2030
Lenacapavir HIV Prevention: Approval and Access Strategy Updates
PEPFAR Funding Pause Threatens Global HIV Progress
Cost-Effectiveness of Digital HIV Self-Testing
HIV Cancer Care Integration in Sub-Saharan Africa
Cost-Effective Cervical Cancer Screening Strategies for Women with HIV in Kwa...
Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prev...
Lenacapavir Injection: A Breakthrough in Global HIV Prevention
Heplisav-B: A Superior Hepatitis B Vaccine for Individuals with HIV